Clinical efficacy and safety of Pyrotinib combined with Utidelone and Capecitabine on advanced HER-2 positive breast cancer
HUANG Yeqiu
ZHANG Yiwen
WAN Dongdong
Abstract：Objective To explore the short-term efficacy and adverse drug events of Pyrotinib combined with Utidelone and Capecitabine in patients with advanced human epidermal growth factor receptor-2(HER-2)positive breast cancer.Methods From June 2020 to June 2022,96 patients with advanced HER-2 positive breast cancer diagnosed by the Department of Oncology,Haimen Hospital,Nantong University were recruited,and randomly divide into the control group(n=48)and study group(n=48).Patients in the control group were treated with Pyrotinib combined with Capecitabine,while those in the study group were treated with Pyrotinib combined with Utidelone and Capecitabine for a total of 6 cycles.Short-term efficacy was compared between groups.Adverse drug events were evaluated based on the Common Terminology Criteria for Adverse Events(CTCAE)v5.0.Results The objective response rate(ORR)of patients in the study group was significantly higher than that of the control group(85.42％vs 66.67％,x2=4.631,P=0.031).The disease control rate(DCR)of the study group was higher than that of control group,but without a significant difference(97.92％vs 93.75％,x2=1.043,P=0.307).The median progression-free survival(PFS,13.6±3.8 months vs 9.8±2.1 months,t=7.652)and overall survival(OS,22.5±5.3 months vs 18.6±4.2 months,t=8.902)of the study group were significantly longer than those of control group(both P＜0.05).The incidence of nausea and vomiting,bone marrow suppression,fatigue,fatigue,and diarrhea in the study group was higher than that of the control group,but without significant differences(x2=0.396,0.677,0.416 and 0.668,respectively;all P＞0.05).The incidence of muscle joint pain and peripheral neuropathy in the study group was significantly higher than that of the control group(x2=7.069 and 11.658,respectively;both P＜0.05).Conclusion The combination of Pyrotinib,Utidelone and Capecitabine has a positive short-term effect on advanced HER-2 positive breast cancer,which effectively prolongs the survival period,with controllable and tolerable adverse drug events.It provides new ideas for clinical treatment.
Keywords：human epidermal growth factor receptor-2breast tumorsPyrotinibUtideloneCapecitabineclinical research
Publication Date：2025-02-28
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 263-266,270 )